解毒益气方联合益元汤对子宫内膜癌的预后影响
|
摘要
目的探索解毒益气方联合益元汤对子宫内膜癌患者预后及免疫功能的影响,为临床治疗子宫内膜癌疾病提供依据。方法选择2017年1月—2017年12月期间收治的子宫内膜癌98例作为观察对象,按数字表法分为解毒益气方联合益元汤治疗组(治疗组)和解毒益气方治疗组(对照组),每组49例,治疗后对两组患者的临床疗效、免疫功能、并发症、中医证候评分、生活质量评分等情况进行分析。结果治疗后治疗组有效率87. 76%,对照组有效率69. 39%,治疗组治疗有效率明显高于对照组(P <0. 05)。治疗后两组Ig A、Ig G水平均明显低于治疗之前,差异有统计学意义(P <0. 05),且治疗组Ig A、Ig G水平显著低于对照组,差异有统计学意义(P <0. 05);治疗后两组NK、CD4+水平均明显高于治疗之前,差异有统计学意义(P <0. 05),且治疗组NK、CD4+水平显著高于对照组,差异有统计学意义(P <0. 05)。治疗后治疗组并发症总发生率3. 38%明显低于对照组并发症总发生率16. 66%,两组比较差异有统计学意义(P <0. 05)。治疗后两组中医证候评分明显低于治疗之前,差异有统计学意义(P <0. 05);且治疗后治疗组的中医证候评分明显低于对照组,差异有统计学意义(P <0. 05)。生活质量方面对照组治疗3周、1个月后比入院时的生活质量总评分显著升高,差异有统计学意义(P <0. 05);治疗组治疗1周、3周、1个月后比入院时的生活质量总评分显著升高,差异有统计学意义(P <0. 05);且治疗组治疗3周和1个月后评分明显高于对照组,差异有统计学意义(P <0. 05)。结论应用解毒益气方联合益元汤对子宫内膜癌具有较好的疗效,不良反应少,具有一定的临床价值。
Objective To explore the prognosis on endometrial carcinoma treated with jiedu yiqi formula and yiyuan decoction and the impacts on immune function so as to provide the evidences for the treatment of endometrial carcinoma. Methods From January 2017 to December 2017,98 patients of endometrial carcinoma were collected as the objects. According to the numeration table,they were divided into a treatment group( treated with jiedu yiqi formula and yiyuan decoction) and a control group( treated with jiedu yiqi formula),49 cases in each one. After treatment,the clinical therapeutic effects,immune function,complications,TCM symptom score and the score of the quality of life were analyzed in the patients of the two groups. Results After treatment,the effective rate was 87. 76% in the treatment group and was 69. 39% in the control group. The effective rate in the treatment group was obviously higher than the control group( P <0. 05). After treatment,the levels of Ig A and Ig G were lower obviously as compared with those before treatment,indicating the statistical significance( P < 0. 05). The levels of Ig A and Ig G in the treatment group were lower significantly than the control group,indicating the significant difference( P < 0. 05). The levels of NK and CD4~+ after treatment were all higher obviously versus before treatment in the two groups,indicating the statistical significance( P < 0. 05). The levels of NK and CD4~+ in the treatment group were higher significantly than those in the control group,indicating the significant differences( P < 0. 05). The total occurrence rate of complications was 3. 38% in the treatment group,which is lower obviously than 16. 66% in the control group after treatment,indicating the significant difference( P < 0. 05). After treatment,TCM symptom scores were all lower obviously than those before treatment in the two groups,indicating the significant difference( P <0. 05). After treatment,the score of TCM symptoms in the treatment group was lower obviously than the control group,indicating the significant difference( P < 0. 05). Regarding the quality of life,the total score was increased significantly in 3 weeks and 1 month of treatment as compared with that when hospitalized in the control group,indicating the significant difference( P < 0. 05). In the treatment group,the total score was increased significantly in 1 week,3 weeks and 1 month of treatment as compared with that when hospitalized in the control group,indicating the significant difference( P < 0. 05).The scores in 3 weeks and 1 month after treatment in the treatment group were higher obviously than the control group,indicating the significant differences( P < 0. 05). Conclusion The combined medication with jiedu yiqi formula and yiyuan decoction is effective on endometrial carcinoma and less in adverse reactions. It is valuable in clinical practice.
Objective To explore the prognosis on endometrial carcinoma treated with jiedu yiqi formula and yiyuan decoction and the impacts on immune function so as to provide the evidences for the treatment of endometrial carcinoma. Methods From January 2017 to December 2017,98 patients of endometrial carcinoma were collected as the objects. According to the numeration table,they were divided into a treatment group( treated with jiedu yiqi formula and yiyuan decoction) and a control group( treated with jiedu yiqi formula),49 cases in each one. After treatment,the clinical therapeutic effects,immune function,complications,TCM symptom score and the score of the quality of life were analyzed in the patients of the two groups. Results After treatment,the effective rate was 87. 76% in the treatment group and was 69. 39% in the control group. The effective rate in the treatment group was obviously higher than the control group( P <0. 05). After treatment,the levels of Ig A and Ig G were lower obviously as compared with those before treatment,indicating the statistical significance( P < 0. 05). The levels of Ig A and Ig G in the treatment group were lower significantly than the control group,indicating the significant difference( P < 0. 05). The levels of NK and CD4~+ after treatment were all higher obviously versus before treatment in the two groups,indicating the statistical significance( P < 0. 05). The levels of NK and CD4~+ in the treatment group were higher significantly than those in the control group,indicating the significant differences( P < 0. 05). The total occurrence rate of complications was 3. 38% in the treatment group,which is lower obviously than 16. 66% in the control group after treatment,indicating the significant difference( P < 0. 05). After treatment,TCM symptom scores were all lower obviously than those before treatment in the two groups,indicating the significant difference( P <0. 05). After treatment,the score of TCM symptoms in the treatment group was lower obviously than the control group,indicating the significant difference( P < 0. 05). Regarding the quality of life,the total score was increased significantly in 3 weeks and 1 month of treatment as compared with that when hospitalized in the control group,indicating the significant difference( P < 0. 05). In the treatment group,the total score was increased significantly in 1 week,3 weeks and 1 month of treatment as compared with that when hospitalized in the control group,indicating the significant difference( P < 0. 05).The scores in 3 weeks and 1 month after treatment in the treatment group were higher obviously than the control group,indicating the significant differences( P < 0. 05). Conclusion The combined medication with jiedu yiqi formula and yiyuan decoction is effective on endometrial carcinoma and less in adverse reactions. It is valuable in clinical practice.
引文
[1]沈敏,唐琳,李健,等.中国汉族成人起病家族性地中海热三例[J].中华临床免疫和变态反应杂志,2016,3(6):75-79.
[2]李莉,马全富,严玲玲,等.武汉市子宫内膜癌及癌前病变的危险因素分析[J].中国妇幼保健,2016,31(6):1139-1142.
[3]Oza AM,Poveda A,Clamp AR,et al. A randomized phaseⅡ(RP2)trial of ridaforolimus(R)compared with progestin(P)or chemotheraphy(C)in female adult patients with advanced endometrial carcinoma[J]. J Clin Oncol,2011,29(15):5009-5013.
[4]杨曦,廖秦平,吴成,等.子宫内膜细胞学检查在子宫内膜癌筛查中的应用[J].中华妇产科杂志,2013,48(12):884-890.
[5]司徒仪.中西医结合妇产科学[M].北京:科学出版社,2007:88.
[6]曹泽毅.中华妇产科学(临床版)[M].北京:人民卫生出版社,2010:618-633.
[7]黄秋良.益元汤加减治疗对子宫内膜癌术后化疗生活质量的影响研究[J].中华临床医师杂志,2014,9(7):315-318.
[8]国家中医药管理局.中药新药临床研究指导原则[S].北京:中国医药科技出版社,2002:135-139.
[9]孙选,陈芊,孔守芳.益元汤加减治疗对子宫内膜癌术后化疗患者生活质量及预后的影响[J].中国中医药科技,2013,18(6):512-514.
[10]张乃怿,吴成,廖秦平.子宫内膜癌的现状和筛查[J].中华临床医师杂志,2013,5(3):804-809.
[11]Armstrong DK. Relapsed ovarian cancer:challenges and management strategies for a chronic disease[J]. Oncologist,2012,7(15):20.
[12]张乃怿,吴成,廖秦平.子宫内膜癌的现状和筛查[J].中华临床医师杂志,2013,11(12):910-913.
[13]姜娜,贾改珍,孙红卫.鲁北地区子宫内膜癌发病因素病例对照研究[J].中华肿瘤防治杂志,2013,10(14):175-178.
[14]乔敏霞,时惠平,董世博. MRI诊断子宫内膜癌价值[J].中华实用诊断与治疗杂志,2013,2(19):51-53.
[15]郎景和.子宫内膜癌诊治的几个问题[J].中华肿瘤防治杂志,2014,16(13):246-248.
[2]李莉,马全富,严玲玲,等.武汉市子宫内膜癌及癌前病变的危险因素分析[J].中国妇幼保健,2016,31(6):1139-1142.
[3]Oza AM,Poveda A,Clamp AR,et al. A randomized phaseⅡ(RP2)trial of ridaforolimus(R)compared with progestin(P)or chemotheraphy(C)in female adult patients with advanced endometrial carcinoma[J]. J Clin Oncol,2011,29(15):5009-5013.
[4]杨曦,廖秦平,吴成,等.子宫内膜细胞学检查在子宫内膜癌筛查中的应用[J].中华妇产科杂志,2013,48(12):884-890.
[5]司徒仪.中西医结合妇产科学[M].北京:科学出版社,2007:88.
[6]曹泽毅.中华妇产科学(临床版)[M].北京:人民卫生出版社,2010:618-633.
[7]黄秋良.益元汤加减治疗对子宫内膜癌术后化疗生活质量的影响研究[J].中华临床医师杂志,2014,9(7):315-318.
[8]国家中医药管理局.中药新药临床研究指导原则[S].北京:中国医药科技出版社,2002:135-139.
[9]孙选,陈芊,孔守芳.益元汤加减治疗对子宫内膜癌术后化疗患者生活质量及预后的影响[J].中国中医药科技,2013,18(6):512-514.
[10]张乃怿,吴成,廖秦平.子宫内膜癌的现状和筛查[J].中华临床医师杂志,2013,5(3):804-809.
[11]Armstrong DK. Relapsed ovarian cancer:challenges and management strategies for a chronic disease[J]. Oncologist,2012,7(15):20.
[12]张乃怿,吴成,廖秦平.子宫内膜癌的现状和筛查[J].中华临床医师杂志,2013,11(12):910-913.
[13]姜娜,贾改珍,孙红卫.鲁北地区子宫内膜癌发病因素病例对照研究[J].中华肿瘤防治杂志,2013,10(14):175-178.
[14]乔敏霞,时惠平,董世博. MRI诊断子宫内膜癌价值[J].中华实用诊断与治疗杂志,2013,2(19):51-53.
[15]郎景和.子宫内膜癌诊治的几个问题[J].中华肿瘤防治杂志,2014,16(13):246-248.